Uncategorized Archives - Page 2 of 2 - Pharmaceutical Business review

Pharmaceutical Business review is using cookies

Continue Learn More

Close

Uncategorized

Research & Development

June 26, 2026

Immunai and Boehringer partner to identify T-cell targets

Immunai and Boehringer Ingelheim have entered a multi-project collaboration to identify new T-cell targets in oncology and autoimmune diseases.

Immunai and Boehringer partner to identify T-cell targets

June 25, 2026

RQ Bio secures $115m to develop influenza antibody programme

Research & Development

RQ Bio secures $115m to develop influenza antibody programme

April 28, 2026

FDA approves AstraZeneca’s Saphnelo for SLE

Approvals

FDA approves AstraZeneca’s Saphnelo for SLE